☆ 4.6 Letter

First update of the living European guideline (EuroGuiDerm) on atopic eczema

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Related references

Note: Only part of the references are listed.
Review Dermatology

Systemic Immunomodulatory Treatments for Atopic Dermatitis Update of a Living Systematic Review and Network Meta-analysis

Aaron M. Drucker et al.

Summary: In this study, a network meta-analysis was conducted to compare the efficacy and safety assessments of systemic treatments for atopic dermatitis. The results indicated that abrocitinib and upadacitinib had slightly higher scores than dupilumab, while upadacitinib at a daily dose of 15 mg showed similar scores to dupilumab.

JAMA DERMATOLOGY (2022)

Add to Collection
Article Dermatology

European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations

A. Wollenberg et al.

Summary: The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. It provides recommendations and detailed information on basic therapy and other treatments for atopic eczema, covering various aspects such as provocation factors, dietary interventions, and occupational and psychodermatological aspects. The guideline also includes specific guidance for pediatric and adolescent patients, as well as pregnant or breastfeeding women.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection
Article Dermatology

European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy

A. Wollenberg et al.

Summary: The evidence- and consensus-based guideline on atopic eczema, developed according to the EuroGuiDerm Guideline and Consensus Statement Development Manual, involves the participation of 29 experts from 12 European countries. The first part of the guideline provides general information, guidance, and detailed information on systemic treatment options, including conventional immunosuppressive drugs, biologics, and janus kinase inhibitors. The second part will cover other aspects of treatment.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection
Article Medicine, General & Internal

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

Thomas Bieber et al.

Summary: The study demonstrated that both 200 mg and 100 mg doses of abrocitinib showed significant efficacy in treating moderate-to-severe atopic dermatitis compared to placebo, with the 200 mg dose being superior to dupilumab in improving itch response. Neither dose of abrocitinib showed significant differences from dupilumab in most other key secondary endpoints at week 16.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection
Article Dermatology

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Eric L. Simpson et al.

Summary: Abrocitinib has been shown to be an effective treatment for atopic dermatitis with a manageable tolerability and safety profile for long-term use, especially when proper patient and dose selection are utilized. The study results suggest that abrocitinib can be used as a long-term therapy for moderate-to-severe atopic dermatitis.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection
Article Dermatology

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial

Lawrence F. Eichenfield et al.

Summary: The study found that oral abrocitinib combined with topical therapy was significantly more effective than placebo with topical therapy in adolescents with moderate-to-severe AD, with an acceptable safety profile.

JAMA DERMATOLOGY (2021)

Add to Collection
Article Dermatology

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial

Jonathan Silverberg et al.

JAMA DERMATOLOGY (2020)

Add to Collection
Article Medicine, General & Internal

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Eric L Simpson et al.

LANCET (2020)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.